Clinical Trials Logo

Myelogenous Leukemia clinical trials

View clinical trials related to Myelogenous Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04965649 Recruiting - Leukemia Clinical Trials

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.

TIPHI
Start date: January 1, 2021
Phase:
Study type: Observational

The aim of this project is to test whether low levels of BcrAbl1, despite the presence of resistance mutations, are related to high levels of innate CD8+ T cells, in the hypothesis that these cells have an anti-tumor role. This research aims to investigate: - An association between the rate of innate CD8+ T cells and the evolution of Phi+ pathologies (Chronic Myeloid Leukemia and Philadelphia chromosome-positive Acute lymphocytic leukemia (Phi+ ALL) carrying a resistance mutation, according to the ELN 2013 and Phi LMC recommendations. - An association between the level of innate CD8+ T cells and the expansion of TKI resistance clones, assessed as the number of BcrAbl1 copies carrying the mutation relative to the number of Abl1 copies.

NCT ID: NCT02203773 Terminated - Clinical trials for Acute Myelogenous Leukemia

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Start date: October 6, 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.

NCT ID: NCT00519090 Terminated - Clinical trials for Myelogenous Leukemia

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

ENEST
Start date: October 2007
Phase: Phase 3
Study type: Interventional

In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

NCT ID: NCT00144703 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.

NCT ID: NCT00133367 Completed - Multiple Myeloma Clinical Trials

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy followed by donor cord blood transplantation.

NCT ID: NCT00100152 Terminated - Clinical trials for Myelodysplastic Syndromes

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Start date: February 2005
Phase: Phase 1
Study type: Interventional

A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).